Significantly declined. After the close of trading on the 14th, it was announced that the performance of the second quarter of the fiscal year ending March 2025 was sold off. Revenue was 3.144 billion thousand yen (8.8% decrease from the same period last year), operating profit was 0.295 billion yen (turning from an operating loss of 0.492 billion yen in the same period last year), but it seems to be discouraged by the decrease in revenue. In addition, UBE announced the start of a co-creation project related to drug repositioning using the Drug Discovery AI Factory, a drug discovery support service specialized in hypothesis generation, but the response has been limited.